- Condition: Healthy
Interventions: Drug: tofacitinib 10 mg; Drug: tofacitinib 5 mg
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Healthy
Interventions: Drug: Maraviroc; Drug: Maraviroc + Boceprevir; Drug: Maraviroc + Telaprevir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Not yet recruiting - verified May 2012 - Condition: Fasting
Interventions: Drug: Azithromycin; Drug: Azithromycin
Sponsors: PT Novell Pharmaceutical Laboratories; PT Novell Pharmaceutical Laboratories
Completed - verified May 2012 - Condition: Non-small Cell Lung Cancer
Intervention: Drug: Crizotinib (Xalkori)
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified May 2012 - Conditions: Narcotic Abuse; Opioid-related Disorders; Analgesia; Chronic Pain
Interventions: Drug: Placebo; Drug: EMBEDA - morphine sulfate/ naltrexone hydrochloride; Drug: morphine sulfate CR crushed.
Sponsors: Pfizer; Pfizer
Completed - verified May 2012 - Condition: Hypercholesterolemia
Interventions: Drug: PBO; Drug: 200mg; Drug: 300mg; Drug: PBO; Drug: PF-04950615; Drug: PF-04950615; Drug: PF-04950615
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified May 2012 - Condition: Inflammation
Interventions: Drug: CsA+Rapamune+CS; Drug: CsA+MMF+CS
Sponsors: Pfizer; Pfizer
Completed - verified May 2012 - Condition: Healthy Volunteers
Interventions: Drug: PH-797804; Drug: PH-797804 + erythromycin
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Condition: Clear Cell Renal Carcinoma
Interventions: Drug: Axitinib; Drug: Placebo
Sponsors: SFJ Pharmaceuticals, Inc.; SFJ Pharmaceuticals, Inc.; Pfizer
Recruiting - verified May 2012 - Condition: Intestinal Obstruction
Interventions: Drug: Loperamide placebo; Drug: Loperamide; Device: Colon Transit; Drug: Sulfasalazine; Drug: Placebo of MNTX and NLX; Drug: Naloxone; Drug: Methylnaltrexone
Sponsors: University Medicine Greifswald; University Medicine Greifswald
Completed - verified May 2012 - Condition: Endometrial Cancer
Intervention: Device: MIrena(LNG-IUS), oral MPA
Sponsors: Korean Gynecologic Oncology Group; Korean Gynecologic Oncology Group
Recruiting - verified May 2012 - Condition: PAIN
Interventions: Drug: PF-06273340 or Placebo; Drug: PF-06273340 or Placebo
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified May 2012 - Condition: Treatment-Resistant Depression
Intervention:
Sponsors: Mclean Hospital; Mclean Hospital; Pfizer; Massachusetts General Hospital
Not yet recruiting - verified May 2012 - Conditions: End Stage Renal Disease; Venous Stenosis
Intervention: Drug: Sirolimus
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; Pfizer
Recruiting - verified May 2012 - Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Access program
Sponsors: Pfizer; Pfizer
Temporarily not available - verified May 2012 - Condition: Hemophilia A
Interventions: Drug: moroctocog alfa (AF-CC); Drug: moroctocog alfa (AF-CC)
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified May 2012 - Conditions: Smoking; Tobacco Use Cessation; Smoking Cessation
Interventions: Behavioral: Brief advice; Behavioral: Compact cessation course; Behavioral: Standard cessation course
Sponsors: University of Heidelberg; University of Heidelberg; Pfizer
Enrolling by invitation - verified April 2012 - Conditions: Heart Failure; Type 2 Diabetes; Glucose Intolerance
Interventions: Drug: Eplerenone; Drug: Spironolactone
Sponsors: Montreal Heart Institute; Montreal Heart Institute; Pfizer
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Etanercept; Drug: placebo
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Conditions: Age-Related Maculopathy; Age-Related Maculopathies; Eye Diseases; Retinal Degeneration; Macular Degeneration
Interventions: Biological: RN6G; Biological: Placebo
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Condition: Healthy
Intervention: Drug: Ziprasidone Hydrochloride
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified April 2012 - Condition: Healthy
Intervention: Drug: Ziprasidone Hydrochloride
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified April 2012 - Condition: Smoking Cessation
Interventions: Drug: placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified May 2012 - Condition: Patients Receiving Mismatched Allogeneic HCT
Intervention: Drug: immunosuppression
Sponsors: South West German Cancer Center; Wolfgang Bethge, MD; medac GmbH; Pfizer; Fresenius Biotech GmbH
Recruiting - verified April 2012 - Conditions: Healthy; Otherwise Healthy Volunteers With Mild or Moderate Hepatic Dysfunction
Interventions: Drug: dacomitinib; Drug: dacomitinib; Drug: dacomitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Chronic Pain
Interventions: Drug: ALO-02; Drug: Placebo
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified May 2012 - Condition: Pneumococcal Infections
Intervention: Biological: Prevnar13 (manufactured by Pfizer)
Sponsors: Agence de Médecine Préventive, France; Agence de Médecine Préventive, France
Not yet recruiting - verified April 2012 - Condition: Type 1 Diabetes
Interventions: Drug: Statin; Drug: Ace Inhibitor; Drug: Placebo; Drug: Combination therapy
Sponsors: Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Juvenile Diabetes Research Foundation; Diabetes UK; British Heart Foundation; Pfizer; The University of Western Australia; The Hospital for Sick Children; University of Oxford; St Thomas' Hospital, London
Recruiting - verified April 2012 - Condition: Advanced Cancer
Interventions: Drug: crizotinib; Drug: crizotinib; Drug: crizotinib; Drug: crizotinib; Drug: crizotinib
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified May 2012 - Condition: Urinary Bladder, Overactive
Interventions: Drug: fesoterodine fumarate; Drug: fesoterodine fumarate; Drug: fesoterodine fumarate; Drug: fesoterodine fumarate; Drug: fesoterodine fumarate
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: inotuzumab ozogamicin; Drug: FLAG (fludarabine, cytarabine and G-CSF); Drug: HIDAC (high dose cytarabine); Drug: cytarabine and mitoxantrone
Sponsors: Pfizer; Pfizer; Union Chimique Belge
Not yet recruiting - verified May 2012 - Condition: Coronary Artery Disease
Interventions: Drug: Atorvastatin; Drug: Rosuvastatin
Sponsors: University of Roma La Sapienza; University of Roma La Sapienza
Not yet recruiting - verified March 2012 - Condition: Pneumococcal Disease
Intervention: Other: Non Intervention
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Gram-Positive Bacterial Infections
Intervention: Drug: Linezolid
Sponsors: Pfizer; Pfizer
Completed - verified March 2012 - Condition: Pain
Interventions: Drug: PF-05089771; Drug: PF-05089771; Drug: PF-05089771
Sponsors: Pfizer; Pfizer
Completed - verified March 2012 - Conditions: Polycystic Ovarian Syndrome; Ovarian Hyperstimulation Syndrome
Intervention: Drug: Cabergoline
Sponsors: Etlik Zubeyde Hanim Womens' Health and Teaching Hospital; Etlik Zubeyde Hanim Womens' Health and Teaching Hospital
Completed - verified April 2012 - Condition: Pain
Interventions: Drug: Ibuprofen/acetaminophen; Drug: Ibuprofen/acetaminophen; Drug: Ibuprofen/acetaminophen; Drug: Ibuprofen; Drug: Placebo
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Conditions: Methicillin-Resistant Staphylococcus Aureus (MRSA); Hospital-Acquired Pneumonia
Interventions: Drug: Linezolid; Drug: Vancomycin
Sponsors: Pfizer; Pfizer; University of Louisville; Henry Ford Hospital; Summa Health System; Sparrow Health System; Jackson Memorial Hospital
Enrolling by invitation - verified May 2012 - Condition: Dupuytren's Disease
Intervention:
Sponsors: Dresden University of Technology; Dresden University of Technology; GWT-TUD GmbH; Pfizer
Recruiting - verified March 2012 - Condition: Management of Moderate to Severe Pain
Interventions: Drug: ALO-02; Drug: Naltrexone block; Drug: ALO-02; Drug: Naltrexone block; Drug: OxyContin; Drug: Naltrexone block
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Cigarette Smoking; Tobacco Use Disorder; Nicotine Dependence; Smoking Cessation
Intervention: Behavioral: Smoking Cessation Decision Aids
Sponsors: Seoul National University Hospital; Seoul National University Hospital; Pfizer
Not yet recruiting - verified March 2012 - Condition: Urinary Bladder, Neurogenic
Interventions: Drug: Fesoterodine 4 mg; Drug: Fesoterodine 8 mg; Drug: Oxybutynin; Drug: Fesoterodine
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Condition: Pain
Intervention: Drug: PF-00345439
Sponsors: Pfizer; Pfizer; Pain Therapeutics, Inc.
Completed - verified March 2012 - Condition: Management of Moderate to Severe Pain
Interventions: Drug: Oxycodone; Drug: Oxycodone; Drug: Oxycodone; Drug: Oxycodone; Drug: Oxycodone
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Management of Moderate to Severe Pain
Interventions: Drug: Oxycodone; Drug: Oxycodone; Drug: Oxycodone; Drug: Oxycodone; Drug: Oxycodone
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Recurrent Glioblastoma
Intervention: Drug: axitinib
Sponsors: Universitair Ziekenhuis Brussel; Bart Neyns; Pfizer
Recruiting - verified March 2012 - Condition: Diffuse Large B-Cell Lymphoma
Intervention: Drug: Rituximab, CMC544, Gemcitabine and Oxaliplatine
Sponsors: Groupe d'Etude des Lymphomes de l'Adulte - Recherche Clinique; Groupe d'Etude des Lymphomes de l'Adulte - Recherche Clinique; Pfizer
Not yet recruiting - verified March 2012 - Condition: Adenoid Cystic Carcinoma
Intervention: Drug: AG-013736 (AXITINIB)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Comprehensive Cancer Network; Pfizer
Recruiting - verified March 2012 - Conditions: Acute Myeloid Leukemia; High-risk Myelodysplastic Syndrome
Interventions: Drug: PF-04449913; Drug: LDAC; Drug: PF-04449913; Drug: Decitabine; Drug: PF-04449913; Drug: Daunorubicin; Drug: cytarabine
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Gram Positive Infection
Interventions: Drug: linezolid; Drug: Placebo
Sponsors: Pfizer; Pfizer
Completed - verified April 2012 - Condition: Inferior Alveolar Nerve Block Failure
Interventions: Drug: Alprazolam; Drug: placebo
Sponsors: Isfahan University of Medical Sciences; Isfahan University of Medical Sciences; Isfahan University School of Dentistry
Completed - verified March 2012 - Condition: Smoking Cessation
Intervention: Other: Smoking cessation
Sponsors: Pfizer; Pfizer; Technical University of Denmark (DTU)
Active, not recruiting - verified April 2012 - Condition: Aggression
Interventions: Dietary Supplement: Placebo; Dietary Supplement: Multi-vitamin/mineral; Dietary Supplement: Docosahexaenoic acid; Dietary Supplement: DHA plus vitamins/minerals
Sponsors: Swansea University; Swansea University
Completed - verified March 2012 - Condition: Healthy
Interventions: Drug: crizotinib; Drug: esomeprazole
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified May 2012 - Condition: Metastatic Uveal Melanoma
Interventions: Drug: Dacarbazine; Drug: Sunitinib
Sponsors: Clatterbridge Centre for Oncology NHS Foundation Trust; Clatterbridge Centre for Oncology NHS Foundation Trust; Cancer Research UK; Pfizer
Recruiting - verified March 2012 - Condition: Meningococcal Infection
Intervention: Procedure: blood sampling
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: PF-05175157; Drug: PF-05175157; Drug: PF-05175157; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Cystic Fibrosis
Intervention:
Sponsors: Foundation for the National Institutes of Health; Foundation for the National Institutes of Health; University of Southern California; University of Minnesota - Clinical and Translational Science Institute; M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; Brigham and Women's Hospital; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Amgen; AstraZeneca; Eli Lilly and Company; Johnson & Johnson; Merck; Pfizer; Critical Path Institute; Predictive Safety Testing Consortium
Recruiting - verified March 2012 - Condition: Dupuytrens Contracture
Interventions: Drug: Xiapex; Procedure: Percutaneous needle fasciotomy
Sponsors: Regionshospitalet Silkeborg; Jeppe Lange, MD
Recruiting - verified February 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: etanercept; Drug: methotrexate
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Condition: Multiple Myeloma
Intervention: Drug: CP-751,871
Sponsors: Pfizer; Pfizer
Completed - verified February 2012 - Condition: Missing Teeth
Interventions: Device: Autogenous bone graft; Drug: InductOs; Procedure: Augmentation surgery
Sponsors: University of Zurich; University of Zurich
Recruiting - verified February 2012 - Conditions: Dysthymic Disorder; Dysthymia; Depression NOS; Chronic Depressive Disorder
Interventions: Drug: Desvenlafaxine; Drug: Placebo
Sponsors: New York State Psychiatric Institute; New York State Psychiatric Institute; Pfizer
Recruiting - verified February 2012 - Conditions: Solid Malignancies; Metastatic Castrate-resistant Prostate Cancer
Intervention: Drug: axitinib
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; Pfizer
Recruiting - verified March 2012 - Condition: Healthy
Interventions: Drug: PF-05180999; Drug: PF-05180999; Drug: PF-05180999; Drug: PF-05180999
Sponsors: Pfizer; Pfizer
Completed - verified April 2012 - Condition: Pain
Interventions: Drug: PF-05089771; Drug: PF-05089771; Drug: PF-05089771; Drug: PF-05089771; Drug: PF-05089771
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: etanercept; Drug: methotrexate (MTX)
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified April 2012 - Condition: Healthy
Interventions: Drug: Voriconazole; Other: microdialysis
Sponsors: Martin-Luther-Universität Halle-Wittenberg; Martin-Luther-Universität Halle-Wittenberg; Medical University of Vienna
Recruiting - verified February 2012 - Condition: Brain Tumor
Intervention: Drug: Irinotecan combination chemotherapy
Sponsors: Seoul National University Hospital; Seoul National University Hospital
Recruiting - verified February 2012 - Conditions: Chronic Kidney Disease; Proteinuria
Intervention: Drug: aliskiren, eplerenon, telmisartan
Sponsors: Medical University of Gdansk; Medical University of Gdansk
Completed - verified February 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: PF-05280586; Biological: MabThera; Biological: Rituxan
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Breast Cancer; Tobacco Dependence
Interventions: Drug: placebo; Drug: varenicline
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Pfizer
Recruiting - verified February 2012 - Condition: Saphenous Vein Graft Disease
Interventions: Drug: Atorvastatin 80 mg daily; Drug: Atorvastatin 10 mg daily
Sponsors: Boca Raton Regional Hospital; Boca Raton Regional Hospital; Pfizer
Recruiting - verified March 2012 - Condition: Hearing Loss, Sensorineural
Interventions: Drug: PF-04958242; Drug: PF-04958242; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Schizophrenia
Interventions: Drug: PF-04958242; Drug: PF-04958242; Drug: PF-04958242; Drug: Placebo
Sponsors: Pfizer; Pfizer
Completed - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: PF-04937319 10 mg; Drug: PF-04937319 50 mg; Drug: PF-04937319 100 mg; Drug: Glimepiride
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Unresectable or Metastatic Hepatocellular Carcinoma
Intervention: Drug: Temsirolimus
Sponsors: University of Tennessee Cancer Institute; University of Tennessee Cancer Institute; Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting - verified March 2012 - Conditions: Analgesia; Acute Pain; Chronic Pain; Narcotic Abuse; Opioid-related Disorders
Interventions: Drug: oxycodone hydrochloride; Drug: oxycodone hydrochloride; Drug: oxycodone hydrochloride; Drug: oxycodone hydrochloride; Drug: marketed oxycodone hydrochloride
Sponsors: Pfizer; Pfizer
Completed - verified February 2012 - Condition: Urinary Bladder, Overactive
Interventions: Drug: tolterodine tartrate; Drug: tolterodine tartrate; Drug: tolterodine tartrate; Drug: tolterodine tartrate; Drug: tolterodine tartrate
Sponsors: Pfizer; Pfizer
Completed - verified January 2012 - A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy SubjectsCondition: Healthy
Interventions: Drug: Pf-04937319; Drug: Pf-04937319; Drug: Pf-04937319
Sponsors: Pfizer; Pfizer
Completed - verified March 2012 - Condition: Juvenile Idiopathic Arthritis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Condition: Healthy
Interventions: Drug: Fluconazole; Drug: Fluconazole
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified January 2012 - Condition: Healthy
Interventions: Drug: Fluconazole; Drug: Fluconazole
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified January 2012 - Condition: Well-differentiated Pancreatic Neuroendocrine Tumor
Intervention: Drug: sunitinib
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Conditions: Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma; Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor; Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1; Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma; Locally Advanced and/or Metastatic Clear Cell Sarcoma; Locally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma
Intervention: Drug: Crizotinib (PF-02341066)
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC; Pfizer
Not yet recruiting - verified January 2012 - Condition: Recurrent Glioblastoma
Intervention: Drug: PF-299804 (Dacomitinib)
Sponsors: Grupo Español de Investigación en Neurooncología; Grupo Español de Investigación en Neurooncología; Pfizer
Recruiting - verified March 2012 - Condition: Vitamin D Deficiency
Interventions: Dietary Supplement: cholecalciferol; Dietary Supplement: cholecalciferol; Dietary Supplement: cholecalciferol; Dietary Supplement: cholecalciferol
Sponsors: Tufts University; Tufts University; Pfizer
Recruiting - verified May 2012 - Condition: Healthy
Interventions: Drug: Donepezil Hydrochloride; Drug: Aricept
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified September 2009 - Condition: Healthy
Interventions: Drug: Donepezil Hydrochloride; Drug: Aricept
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified September 2009 - Condition: Glioblastoma Multiforme
Interventions: Drug: Axitinib; Radiation: Radiation Therapy
Sponsors: University of Cincinnati; University of Cincinnati; Pfizer
Recruiting - verified January 2012 - Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Drug: CP-690,550; Drug: CP-690, 550
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Crizotinib
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified May 2012 - Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Condition: Healthy
Intervention: Drug: Atorvastatin
Sponsors: Ranbaxy Inc.; Ranbaxy Laboratories Limited
Completed - verified December 2011 - Condition: Healthy
Intervention: Drug: Atorvastatin
Sponsors: Ranbaxy Inc.; Ranbaxy Laboratories Limited
Completed - verified December 2011 - Condition: Postoperative Dental Pain
Interventions: Drug: PF-05089771; Other: Placebo; Drug: PF-05089771; Other: Placebo; Drug: PF-05089771; Other: Placebo; Drug: Ibuprofen; Other: Placebo; Other: Placebo; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Infection in Solid Organ Transplant Recipients
Intervention: Biological: Pneumococcal Conjugate Vaccine 13 (PCV13)
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified February 2012 - Condition: Peripheral Neuropathic Pain
Intervention: Other: No intervention. Non-interventional study
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified April 2012 - Condition: Colorectal Cancer
Intervention: Drug: PF-0332991, 5-FU, oxaliplatin
Sponsors: Georgetown University; Georgetown University; Pfizer
Recruiting - verified December 2011 - Conditions: Schizophrenia; Anxiety-comorbidity to Schizophrenia
Interventions: Drug: Pregabalin; Drug: Pregabalin Placebo Capsules
Sponsors: University of Aarhus; University of Aarhus; Albert Einstein College of Medicine of Yeshiva University; GCP-unit at Aarhus University Hospital, Aarhus, Denmark; The Hospital Pharmcacy North Denmark Region, Denmark; Pfizer
Not yet recruiting - verified December 2011 - Condition: Type 2 Diabetic Nephropathy
Interventions: Drug: PF-03882845; Drug: PF-03882845; Drug: PF-03882845; Drug: Spironolactone; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Coronary Artery Disease
Interventions: Drug: Ranolazine; Drug: Amlodipine
Sponsors: University of Roma La Sapienza; University of Roma La Sapienza
Not yet recruiting - verified December 2011 - Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550 or Placebo; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Clear Cell, Metastatic Renal Cell Carcinoma
Intervention: Drug: Sunitinib
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Pfizer
Not yet recruiting - verified December 2011 - Condition: Major Depression
Intervention: Drug: Desvenlafaxine
Sponsors: Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine; Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine; Pfizer
Recruiting - verified December 2011 - Condition: Acute Coronary Syndrome
Interventions: Drug: Pre-procedural High dose atorvastatin loading; Drug: No pre-procedural high-dose atorvastatin loading
Sponsors: The Korean Society of Circulation; The Korean Society of Circulation
Recruiting - verified December 2011 - Condition: Major Depressive Disorder
Intervention: Drug: Venlafaxine ER
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Healthy Participants
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Completed - verified December 2011 - Condition: Healthy
Interventions: Drug: tofacitinib (CP-690,550) modified-release formulation A; Drug: tofacitinib (CP-690,550) modified-release formulation B1; Drug: tofacitinib (CP-690,550) modified-release formulation A; Drug: tofacitinib (CP-690,550) modified-release formulation B1; Drug: tofacitinib (CP-690,550) modified-release formulation B2; Drug: tofacitinib (CP-690,550) immediate-release formulation
Sponsors: Pfizer; Pfizer
Completed - verified January 2012 - Condition: Healthy Volunteers
Interventions: Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804
Sponsors: Pfizer; Pfizer
Completed - verified February 2012 - Condition: Non-Melanoma Skin Carcinoma
Interventions: Drug: voriconazole (Vfend); Other: no voriconazole (Vfend)
Sponsors: Pfizer; Pfizer; University of Southern California
Completed - verified December 2011 - Condition: Proliferative Diabetic Retinopathy
Intervention: Drug: Macugen ® (pegaptanib sodium)
Sponsors: Valley Retina Institute; Valley Retina Institute; Pfizer
Active, not recruiting - verified December 2011 - Condition: Renal Cell Carcinoma
Intervention: Drug: Axitinib
Sponsors: Pfizer; Pfizer
Available - verified May 2012 - Condition: Diabetic Peripheral Neuropathy
Interventions: Drug: Pregabalin; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Healthy
Interventions: Drug: PF-06291874 or placebo; Drug: PF-06291874 or Placebo
Sponsors: Pfizer; Pfizer
Terminated - verified January 2012 - Condition: Cutaneous Lupus Erythematosus
Interventions: Drug: PD-0360324; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Osteoporosis
Intervention: Drug: Bazedoxifene
Sponsors: Pfizer; Pfizer
Enrolling by invitation - verified May 2012 - Condition: Healthy
Interventions: Drug: Alivium®; Drug: Ibuprofen
Sponsors: Pfizer; Pfizer
Completed - verified February 2012 - Condition: Advanced Solid Tumors
Interventions: Drug: AG-013736; Drug: AG-013736; Drug: AG-013736; Drug: AG-013736; Drug: AG-013736; Drug: AG-013736
Sponsors: Pfizer; Pfizer
Completed - verified February 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: PF-05190457; Drug: PF-05190457; Drug: PF-05190457; Drug: PF-05190457; Drug: PF-05190457; Drug: PF-05190457; Drug: PF-05190457; Drug: PF-05190457
Sponsors: Pfizer; Pfizer
Completed - verified January 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Simvastatin; Drug: PF-05175157
Sponsors: Pfizer; Pfizer
Completed - verified December 2011 - Condition: Healthy
Intervention: Drug: PF-04991532
Sponsors: Pfizer; Pfizer
Completed - verified January 2012 - Condition: Crohn's Disease
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Enrolling by invitation - verified May 2012 - Condition: Colorectal Cancer
Interventions: Drug: Axitinib; Drug: Bevacizumab; Drug: 5-FU; Drug: 5-FU; Drug: Leucovorin; Drug: Oxaliplatin
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Pfizer
Recruiting - verified January 2012 - Condition: Major Depressive Disorder
Intervention: Drug: desvenlafaxine
Sponsors: University of British Columbia; University of British Columbia; Pfizer
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: PF-04991532; Drug: PF-04991532; Drug: PF-04991532; Drug: PF-0499132; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: GIST
Intervention: Other: non-interventional
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Tourette's Syndrome
Interventions: Drug: PF-03654746; Drug: Placebo; Drug: Placebo; Drug: PF-03654746
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: docetaxel and epirubicin; Drug: docetaxel and epirubicin plus endostatin
Sponsors: Xijing Hospital; Xijing Hospital
Recruiting - verified November 2011 - Condition: Ulcerative Colitis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified May 2012 - Condition: Ulcerative Colitis
Interventions: Drug: Placebo; Drug: CP690,550; Drug: CP690,550
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified May 2012 - Condition: Ulcerative Colitis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified May 2012 - Condition: Ulcerative Colitis
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: PF-00299804 Plus Blinded Doxycycline Placebo; Drug: PF-00299804 Plus Blinded Doxycycline; Drug: PF-00299804
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Pain; Migraine Disorders
Interventions: Biological: PF-04427429; Other: Normal saline
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Postherpetic Neuralgia ( PHN )
Interventions: Drug: Lyrica (pregabalin); Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Epilepsy, Partial Seizures; Epilepsy, Primary Generalized Tonic-Clonic Seizures
Intervention: Drug: Pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Painful Diabetic Peripheral Neuropathy
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Healthy
Interventions: Drug: Vycavert; Drug: Norco
Sponsors: Pfizer; Pfizer
Completed - verified February 2012 - Condition: Smoking Cessation
Interventions: Drug: Placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Healthy
Interventions: Drug: ALO-02 (Oxycodone Naltrexone); Drug: ALO-02 (Oxycodone Naltrexone); Drug: ALO-02 (Oxycodone Naltrexone)
Sponsors: Pfizer; Pfizer
Completed - verified January 2012 - Condition: Intra-abdominal Infections
Interventions: Drug: Metronidazole; Drug: Ceftriaxone sodium
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Optic Neuritis; Multiple Sclerosis
Interventions: Drug: Phenytoin; Drug: Placebo
Sponsors: University College, London; University College, London; National Multiple Sclerosis Society; Multiple Sclerosis Society of Great Britain and Northern Ireland
Not yet recruiting - verified October 2011 - Condition: Type 2 Diabetes
Intervention:
Sponsors: Foundation for the National Institutes of Health; Foundation for the National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Juvenile Diabetes Research Foundation; Amylin Pharmaceuticals, Inc.; Merck; Pfizer; Eli Lilly and Company; Takeda Global Research & Development Center, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Novartis
Recruiting - verified October 2011 - Condition: Human Volunteers
Intervention: Drug: PF-04937319 / ketoconazole
Sponsors: Pfizer; Pfizer
Completed - verified November 2011 - Conditions: Poliomyelitis; Haemophilus Influenzae Type b Disease; Hepatitis B; Diphtheria; Pertussis; Tetanus
Interventions: Biological: Combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and Haemophilus influenzae type b vaccine (GSK217744) - Formulation A; Biological: Combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and Haemophilus influenzae type b vaccine (GSK217744) - Formulation B; Biological: Infanrix hexaTM; Biological: Pfizer's 13-valent pneumococcal polysaccharide conjugate vaccine (Prevenar 13®)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Condition: Plaque Psoriasis Patients
Intervention: Other: Enbrel treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Vaccines; Meningococcal Vaccines
Interventions: Biological: rLP2086 + MCV4 + Tdap; Biological: MCV4 + Tdap + saline; Biological: rLP2086 + saline
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Vaccines; Meningococcal Vaccines
Interventions: Biological: rLP2086 and Gardasil; Biological: rLP2086; Biological: Gardasil
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Healthy
Intervention: Biological: 13-valent pneumococcal vaccine
Sponsors: Pfizer; Pfizer
Enrolling by invitation - verified April 2012 - Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Sitaxentan sodium
Sponsors: Pfizer; Pfizer
Completed - verified September 2011 - Condition: Primary Adrenal Insufficiency
Interventions: Drug: Hydrocortisone intramuscular first; Drug: Hydrocortisone subcutaneously first
Sponsors: University of Wuerzburg; Bruno Allolio
Not yet recruiting - verified October 2011 - Condition: Healthy
Interventions: Drug: Sequence 1 - Treatment A: Controlled Release Pregabalin; Drug: Sequence 1 - Treatment B: Controlled Release Pregabalin; Drug: Sequence 1 - Treatment C:Controlled Release Pregabalin; Drug: Sequence 1 - Treatment D: Controlled Release Pregabalin; Drug: Sequence 1 - Treatment E: Immediate Release Pregabalin; Drug: Sequence 2 - Treatment B: Controlled Release Pregabalin; Drug: Sequence 2 - Treatment D: Controlled Release Pregabalin; Drug: Sequence 2 - Treatment A: Controlled Release Pregabalin; Drug: Sequence 2 - Treatment C: Controlled Release Pregabalin; Drug: Sequence 2 - Treatment E: Immediate Release Pregabalin; Drug: Sequence 3 - Treatment C: Controlled Release Pregabalin; Drug: Sequence 3 - Treatment A: Controlled Release Pregabalin; Drug: Sequence 3 - Treatment D: Controlled Release Pregabalin; Drug: Sequence 3 - Treatment B: Controlled Release Pregabalin; Drug: Sequence 3 - Treatment E: Immediate Release Pregabalin; Drug: Sequence 4 - Treatment D: Controlled Release Pregabalin; Drug: Sequence 4 - Treatment C: Controlled Release Pregabalin; Drug: Sequence 4 - Treatment B: Controlled Release Pregabalin; Drug: Sequence 4 - Treatment A: Controlled Release Pregabalin; Drug: Sequence 4 - Treatment E: Immediate Release Pregabalin
Sponsors: Pfizer; Pfizer
Completed - verified April 2012 - Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine; Drug: desvenlafaxine; Drug: desvenlafaxine
Sponsors: Pfizer; Pfizer
Completed - verified December 2011 - Condition: Major Depressive Disorder
Interventions: Drug: venlafaxine ER 75 mg/day (fixed dose); Drug: venlafaxine ER 75 mg/day to 225 mg/day (flexible dose); Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Epilepsies, Partial
Intervention: Drug: gabapentin
Sponsors: Pfizer; Pfizer
Enrolling by invitation - verified March 2012 - Conditions: Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Hepatocellular
Interventions: Drug: Crizotinib plus VEGF inhibitor combinations; Drug: Crizotinib plus axitinib; Drug: Crizotinib plus sunitinib; Drug: Crizotinib plus axitinib; Drug: Crizotinib plus sunitinib; Drug: Crizotinib plus bevacizumab; Drug: Crizotinib plus sorafenib
Sponsors: Pfizer; Pfizer
Withdrawn - verified December 2011 - Condition: Rheumatoid Arthritis (RA)
Interventions: Drug: tDMARDs; Drug: biodmards
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Healthy
Interventions: Drug: Apixaban; Drug: Apixaban
Sponsors: Pfizer; Pfizer
Completed - verified October 2011 - Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Drug: PF-00299804
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Pfizer
Recruiting - verified February 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Placebo; Drug: PF-04937319 - 3mg; Drug: PF-04937319 - 20mg; Drug: PF-04937319 - 50mg; Drug: PF-04937319 - 100mg; Drug: Sitagliptin - 100mg
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Primary Ovarian Insufficiency; Vaginitis; Metrorrhagia; Menopause
Interventions: Drug: Premarin reference tablet (fasted); Drug: Premarin new tablet (fasted); Drug: Premarin reference tablet (fed); Drug: Premarin new tablet (fed)
Sponsors: Pfizer; Pfizer
Completed - verified March 2012 - Condition: Renal Cell Carcinoma
Intervention:
Sponsors: Cancer Foundation, China; Cancer Foundation, China; Pfizer
Not yet recruiting - verified September 2011 - Condition: Benign Prostatic Hyperplasia
Interventions: Drug: Early combination therapy; Drug: Delayed combination therapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified July 2011 - Condition: Transthyretin Familial Amyloid Polyneuropathy
Intervention: Drug: tafamidis
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Left Ventricular Dysfunction Post Myocardial Infarction
Intervention: Other: Prospective Observational
Sponsors: Pfizer; Pfizer
Completed - verified September 2011 - Conditions: Pneumococcal Vaccine; Streptococcus Pneumoniae
Intervention: Biological: 7-valent vaccine injection
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified April 2012 - Condition: Knee Osteoarthritis
Interventions: Drug: SD-6010; Drug: SD-6010; Drug: Placebo
Sponsors: Pfizer; Pfizer
Withdrawn - verified January 2012 - Condition: DUPUYTREN'S CONTRACTURE
Interventions: Drug: Xiapex; Procedure: surgery
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained-release 50 mg/day; Drug: desvenlafaxine succinate sustained-release 100 mg/day; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Healthy
Interventions: Drug: PF-05297909 25 mg; Drug: PF-05297909 100 mg; Drug: PF-05297909 250 mg; Drug: PF-05297909 525 mg; Drug: PF-05297909 525 mg
Sponsors: Pfizer; Pfizer
Completed - verified March 2012 - Condition: Fibromyalgia
Interventions: Drug: Pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Hypercholesterolemia; Dyslipidemias; Hyperlipidemias; Lipid Metabolism Disorders; Metabolic Diseases
Interventions: Biological: PF-04950615; Biological: PF-04950615; Biological: PF-04950615; Biological: PF-04950615
Sponsors: Pfizer; Pfizer
Completed - verified March 2012 - Condition: Osteoarthritis of the Knee
Interventions: Drug: Meloxicam; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Migraine Disorders
Interventions: Drug: Non-steroidal anti-inflammatory drug (NSAID); Drug: Triptan
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified September 2011 - Condition: Carcinoid Tumor
Intervention: Drug: Axitinib
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Comprehensive Cancer Network; Pfizer
Recruiting - verified March 2012 - Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: dovitinib
Sponsors: Asan Medical Center; Asan Medical Center
Recruiting - verified September 2011 - Condition: Chronic Noncancer Pain
Intervention: Drug: oxycodone HCl and naltrexone HCl extended-release capsules
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified May 2012 - Condition: Post-surgical Dental Pain
Interventions: Drug: PF-04531083; Other: Placebo; Drug: PF-04531083; Other: Placebo; Drug: Ibuprofen; Other: Placebo; Other: Placebo; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Metastatic Renal Cell Carcinoma
Interventions: Biological: PF-04856884; Drug: AG-013736
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Hemophilia A; Hemophilia B
Interventions: Biological: PF-05280602; Biological: PF-05280602; Biological: PF-05280602; Biological: PF-05280602; Biological: PF-05280602; Biological: PF-05280602
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Psoriasis
Intervention:
Sponsors: Pfizer; Pfizer; University of Connecticut School of Pharmacy and Hartford Hospital
Completed - verified September 2011 - Condition: Schizophrenia
Interventions: Drug: PF-05180999; Drug: Placebo
Sponsors: Pfizer; Pfizer
Completed - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: PF-05175157; Drug: Placebo
Sponsors: Pfizer; Pfizer
Completed - verified May 2012 - Conditions: Early Breast Cancer (Phase 2); Advanced Breast Cancer (Phase 1b)
Interventions: Drug: PF-04691502; Drug: PF-04691502 in combination with Letrozole; Drug: Letrozole
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified May 2012 - Conditions: Immune Reconstitution Inflammatory Syndrome; Immune Reconstitution Syndrome; Tuberculosis; HIV-infection/Aids
Interventions: Drug: Dexamethasone; Drug: Atorvastatin; Drug: Naproxen; Drug: Placebo
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Pfizer; Minnesota Medical Foundation
Not yet recruiting - verified April 2012 - Condition: Endometrial Neoplasms
Interventions: Drug: PF-04691502; Drug: PF-05212384; Drug: PF-04691502; Drug: PF-05212384
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Healthy
Interventions: Drug: triazolam liquid oral drops; Drug: triazolam tablets
Sponsors: Pfizer; Pfizer
Completed - verified October 2011 - Condition: Juvenile Idiopahtic Arthritis
Intervention: Drug: etanercept
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Renal Cell Carcinoma
Intervention: Drug: Temsirolimus
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Intervention: Other: SC anti-TNF
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention: Other: SC anti-TNF
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified April 2012 - Condition: Ankylosing Spondylitis
Intervention: Drug: Enbrel
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified April 2012 - Condition: Renal Impairment
Interventions: Drug: crizotinib; Drug: crizotinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Pneumococcal Infection
Interventions: Biological: 13-valent Pneumococcal Conjugate Vaccine; Biological: 13-valent Pneumococcal Conjugate Vaccine; Biological: 13-valent Pneumococcal Conjugate Vaccine
Sponsors: Pfizer; Pfizer
Completed - verified February 2012 - Condition: Osteoporosis, Postmenopausal
Interventions: Drug: Bazedoxifene; Drug: Bisphosphonate; Drug: Raloxifene
Sponsors: Pfizer; Pfizer
Enrolling by invitation - verified May 2012 - Conditions: Arthritis; Rheumatoid; High Dose
Intervention: Drug: Methotrexate (MTX)
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Obese; Growth Hormone Secretion Abnormality
Intervention: Drug: Growth hormone treatment
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Pfizer
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Biological: trastuzumab; Drug: Neratinib
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Pfizer
Recruiting - verified March 2012 - Condition: Pediatric Psoriasis
Intervention: Drug: Enbrel group
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Conditions: Hematopoietic Stem Cell Transplant; Hematologic Malignancy; Voriconazole
Intervention: Drug: Prospective Voriconazole therapeutic drug monitoring
Sponsors: Johns Hopkins University; Johns Hopkins University; Pfizer
Not yet recruiting - verified July 2011 - Condition: Exudative Age-related Macular Degeneration
Interventions: Drug: iSONEP; Drug: 0.5 mg iSONEP and ranibizumab or bevacizumab; Drug: 4.0 mg iSONEP with ranibizumab or bevacizumab; Drug: ranibizumab or bevacizumab
Sponsors: Lpath, Inc.; Lpath, Inc.; Pfizer
Active, not recruiting - verified January 2012 - Condition: Lupus Erythematosus, Systemic
Interventions: Biological: PF-04236921; Biological: PF-04236921; Biological: PF-04236921; Biological: PF-04236921
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Therapeutic Equivalency
Interventions: Drug: methylprednisolone; Drug: methylprednisolone
Sponsors: Pfizer; Pfizer
Withdrawn - verified October 2011 - Condition: Therapeutic Equivalency
Interventions: Drug: methylprednisolone; Drug: methylprednisolone
Sponsors: Pfizer; Pfizer
Withdrawn - verified October 2011 - Condition: Therapeutic Equivalency
Interventions: Drug: methylprednisolone; Drug: methylprednisolone
Sponsors: Pfizer; Pfizer
Withdrawn - verified October 2011 - Condition: Smoking Cessation
Interventions: Behavioral: Smoking counseling; Behavioral: Smoking counseling; Drug: Placebo; Drug: Varenicline
Sponsors: University of California, San Francisco; University of California, San Francisco; Pfizer
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Other: ADT Therapy; Drug: Axitinib; Procedure: Prostatectomy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: ATRA; Drug: ATO; Drug: GO (Gemtuzumab ozogamicin); Drug: Methylprednisolone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified March 2012 - Condition: Infection
Intervention: Drug: metronidazole IV 500 mg
Sponsors: Pfizer; Pfizer
Completed - verified September 2011 - Condition: Schizophrenia
Interventions: Drug: PF-04958242; Drug: PF-04958242; Drug: PF-04958242; Drug: PF-04958242; Drug: Placebo
Sponsors: Pfizer; Pfizer
Completed - verified January 2012 - Conditions: Neurofibromatosis; NF1; Plexiform Neurofibromas
Intervention: Drug: Sutent®/Sunitinib
Sponsors: Indiana University; Indiana University; Department of Defense; Pfizer
Recruiting - verified March 2012 - Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: sunitinib malate dose escalation; Drug: sunitinib malate
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified May 2012 - Condition: Crohn's Disease
Interventions: Drug: Placebo; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Healthy Volunteers
Interventions: Drug: Myrin P Forte; Drug: Single drug references
Sponsors: Pfizer; Pfizer
Completed - verified May 2012 - Condition: Healthy
Interventions: Drug: CP-601,927; Drug: CP-601,927; Drug: CP-601,927; Drug: Placebo; Drug: CP-601,927; Drug: Placebo
Sponsors: Pfizer; Pfizer
Withdrawn - verified September 2011 - Condition: Crohn's Disease
Interventions: Drug: Placebo; Drug: CP-690,550; Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Healthy
Intervention: Other: Formulation buffers
Sponsors: Pfizer; Pfizer
Completed - verified July 2011 - Condition: Human Volunteers
Intervention: Drug: Simvastatin/PF-03882845
Sponsors: Pfizer; Pfizer
Completed - verified September 2011 - Condition: Overactive Bladder
Intervention: Behavioral: Health education intervention (HEI)
Sponsors: Samsung Medical Center; Samsung Medical Center; Pfizer
Recruiting - verified January 2012 - Condition: Renal Cell Carcinoma
Intervention: Drug: Temsirolimus (pre surgery)
Sponsors: St. Joseph's Healthcare Hamilton; St. Joseph's Healthcare Hamilton; McMaster University; Pfizer
Active, not recruiting - verified March 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: PF-05231023; Drug: PF-05231023; Drug: PF-05231023; Drug: PF-05231023; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention: Drug: Metformin/CP-690,550
Sponsors: Pfizer; Pfizer
Completed - verified August 2011 - Condition: Epilepsy
Intervention: Drug: Anti-epileptic drug (AED)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012 - Condition: Pneumococcal Vaccines
Interventions: Biological: 13-valent pneumococcal conjugate vaccine; Biological: INFANRIX hexa; Drug: Paracetamol; Biological: 13-valent pneumococcal conjugate vaccine; Biological: INFANRIX hexa; Drug: Ibuprofen; Biological: 13-valent pneumococcal conjugate vaccine; Biological: INFANRIX hexa; Drug: Paracetamol; Biological: 13-valent pneumococcal conjugate vaccine; Biological: INFANRIX hexa; Drug: Ibuprofen; Biological: 13-valent pneumococcal conjugate vaccine; Biological: INFANRIX hexa
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified April 2012 - Condition: Epilepsy, Partial Seizures
Interventions: Drug: Pregabalin add-on therapy; Drug: Pregabalin add-on therapy; Drug: Pregabalin add-on therapy
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Hypertension
Interventions: Drug: Doxazosin 4 mg Japanese marketed IR tablet; Drug: Doxazosin 4 mg ODT with water; Drug: Doxazosin 4 mg ODT without water
Sponsors: Pfizer; Pfizer
Completed - verified October 2011 - Condition: Healthy
Interventions: Drug: Treatment A; Drug: Treatment B
Sponsors: Pfizer; Pfizer
Completed - verified August 2011 - Condition: Fibromyalgia
Intervention: Drug: Pregabalin
Sponsors: Newton-Wellesley Hospital; Newton-Wellesley Hospital; Pfizer
Not yet recruiting - verified July 2011 - Conditions: Crohn's Disease; Ileitis; Ileo-colonic and Colonic Crohn's Disease; Granulomatous Colitis; Regional Enteritis
Interventions: Procedure: lumbar puncture; Drug: lumbar puncture
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Condition: Healthy Volunteers
Interventions: Drug: PF-06273588; Drug: PF-06273588
Sponsors: Pfizer; Pfizer
Completed - verified September 2011 - Condition: Fibromyalgia
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Aspergillosis, Aspergilloma; Candidemia, Candidiasis; Cryptococcal Meningitis, Pulmonary Cryptococcosis; Fusariosis; Scedosporiosis
Interventions: Drug: Voriconazole; Drug: Voriconazole
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Pneumococcal Disease
Intervention: Biological: Prevenar 13
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Nondependent Opioid Abuse, Episodic
Interventions: Drug: Placebo; Drug: MS Contin (morphine sulfate, controlled release); Drug: EMBEDA (morphine sulfate / naltrexone hydrochloride)
Sponsors: Pfizer; Pfizer
Completed - verified September 2011 - Condition: Pneumococcal Infections
Interventions: Biological: vaccine-13vPnC; Biological: vaccine-13vPnC
Sponsors: Pfizer; Pfizer
Completed - verified February 2012 - Condition: Migraine Disorders
Interventions: Drug: Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap); Drug: Triptan monotherapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified June 2011 - Condition: Migraine Disorders
Interventions: Drug: Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap); Drug: Single-entity oral triptans
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified June 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: PF-05175157 or Placebo; Drug: PF-05175157 or Placebo; Drug: PF-05175157 or Placebo; Drug: PF-05175157 or Placebo; Drug: PF-05175157 or Placebo
Sponsors: Pfizer; Pfizer
Completed - verified February 2012 - Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related SurgeryCondition: Thrombosis, Venous
Interventions: Drug: dalteparin; Drug: enoxaparin; Drug: fondaparinux; Drug: unfractionated heparin
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011 - Condition: Pulmonary Disease, Chronic Obstructive
Intervention: Procedure: Education
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified May 2012 - Conditions: Primary Open Angle Glaucoma; Ocular Hypertension
Interventions: Drug: latanoprost 75 ug; Drug: latanoprost 100 ug; Drug: latanoprost 125 ug; Drug: latanoprost 50 ug
Sponsors: Pfizer; Pfizer
Completed - verified June 2011 - Condition: HIV
Intervention: Drug: Maraviroc
Sponsors: Kirby Institute; Kirby Institute; ViiV Healthcare; Pfizer
Recruiting - verified August 2011 - Condition: Kidney Transplantation
Interventions: Drug: Tofacitinib; Drug: Tofacitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: prednisone; Other: prednisone; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: PF-05190457 or Placebo; Drug: PF-05190457 or Placebo; Drug: PF-05190457 or Placebo; Drug: PF-05190457 or Placebo; Drug: PF-05190457 or Placebo; Drug: PF-05190457 or Placebo; Drug: PF-05190457 or Placebo
Sponsors: Pfizer; Pfizer
Terminated - verified May 2012 - Condition: Healthy
Interventions: Other: Study formula feeding; Other: Human milk feeding; Other: Mixed feeding
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Healthy
Interventions: Drug: PF-04620110 or Placebo; Drug: PF-04620110 or Placebo; Drug: PF-04620110 or Placebo
Sponsors: Pfizer; Pfizer
Completed - verified January 2012 - Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Major Depressive Disorder
Interventions: Drug: desvenlafaxine succinate sustained release; Drug: fluoxetine; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Asthma
Interventions: Drug: Tiotropium bromide; Drug: Tiotropium bromide; Drug: Tiotropium bromide; Drug: Tiotropium bromide
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified May 2012 - Conditions: Healthy; Drug Interaction
Interventions: Drug: PF-04991532 alone; Drug: PF-04991532 + cyclosporine
Sponsors: Pfizer; Pfizer
Completed - verified September 2011 - Condition: Smoking Cessation
Interventions: Drug: Varenicline Tartrate; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Type 2 Diabetes Mellitus; Healthy
Interventions: Drug: PF-04991532; Drug: PF-04991532; Drug: PF-04991532; Drug: PF-04991532
Sponsors: Pfizer; Pfizer
Completed - verified February 2012 - Conditions: Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose Metabolism Disorders
Interventions: Drug: PF-04991532; Drug: Placebo; Drug: PF-04991532
Sponsors: Pfizer; Pfizer
Completed - verified September 2011 - Condition: Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML)
Interventions: Drug: Bosutinib; Drug: Bosutinib
Sponsors: Pfizer; Pfizer
Completed - verified November 2011 - Condition: Healthy
Interventions: Drug: Tafamidis meglumin; Drug: Tafamidis meglumin; Drug: Placebo
Sponsors: Pfizer; Pfizer
Completed - verified September 2011 - Conditions: Diarrhea; Clostridium Difficile
Intervention: Drug: Tygacil
Sponsors: Michigan State University; Gary E. Stein, Pharm.D.; Pfizer
Recruiting - verified January 2012 - Conditions: Carcinoma, Renal Cell; Lymphoma, Mantle-Cell
Intervention: Other: Temsirolimus (Non-Interventional Study)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Staphylococcal Infections; Staphylococcal Vaccines; Bacterial Infections; Staphylococcal Skin Infections
Interventions: Biological: SA4Ag vaccine low dose; Procedure: Blood draw; Procedure: Colonization swab sample; Biological: SA4Ag vaccine mid dose; Procedure: Blood sample; Procedure: Colonization swab sample; Biological: SA4Ag vaccine high dose; Procedure: Blood draw; Procedure: Colonization swab sample; Biological: Placebo; Procedure: Blood draw; Procedure: Colonization swab sample
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Pain
Interventions: Drug: PF-05089771; Drug: PF-05089771; Drug: PF-05089771; Drug: PF-05089771
Sponsors: Pfizer; Pfizer
Completed - verified October 2011 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone Propionate; Drug: Placebo for Fluticasone Propionate
Sponsors: Pfizer; Pfizer
Completed - verified February 2012 - Condition: Pulmonary Arterial Hypertension
Intervention: Drug: sildenafil citrate
Sponsors: Pfizer; Pfizer
Completed - verified November 2011 - Condition: Glaucoma
Intervention:
Sponsors: University Hospital Tuebingen; University Hospital Tuebingen; Pfizer
Recruiting - verified January 2012 - Conditions: Leukemia; Acute Lymphoblastic Leukemia
Interventions: Drug: Inotuzumab Ozogamycin; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Mesna; Drug: Vincristine; Drug: Dexamethasone; Drug: Pegfilgrastim; Drug: Methotrexate; Drug: Ara-C; Drug: Inotuzumab Ozogamycin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified April 2012 - Conditions: Complicated Skin and Structure Infection; Nosocomial Pneumonia
Interventions: Drug: Linezolid; Drug: Vancomycin; Drug: Linezolid; Drug: Vancomycin
Sponsors: Pfizer; Pfizer; University of Maryland; Lodise & Lodise, LLC
Completed - verified April 2012 - Condition: Rupture of Anterior Cruciate Ligament
Interventions: Drug: parecoxib, valdecoxib, etoricoxib; Drug: Dexamethasone; Drug: parecoxib, valdecoxib, parecoxib and dexamethasone
Sponsors: Asker & Baerum Hospital; Asker & Baerum Hospital
Completed - verified May 2011 - Conditions: HIV; Impaired Cognition
Interventions: Drug: standard care; Drug: novel treatment
Sponsors: Imperial College London; Imperial College London; Pfizer
Not yet recruiting - verified June 2011 - Condition: Lumbar Spinal Fusions
Interventions: Drug: Pregabalin 150 mg; Drug: Placebo
Sponsors: Hospital for Special Surgery, New York; Hospital for Special Surgery, New York; Pfizer
Recruiting - verified June 2011 - Condition: Turner Syndrome
Intervention: Drug: somatotropin
Sponsors: University of North Carolina, Chapel Hill; Marsha Davenport, MD; Pfizer
Recruiting - verified January 2012 - Condition: Allergic Asthma
Interventions: Drug: Roflumilast; Drug: Placebo
Sponsors: Nycomed; Nycomed; Pfizer
Completed - verified May 2012
 |
Pfizer - Database of Clinical Trials by Pharmaceutical Companies |
